Conclusion of an amendment to global License Agreement with Menarini Group

Read More

Ryvu Therapeutics H1 2023 Financial Report

Read More

Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology

Read More

Conclusion of a financing agreement with the Medical Research Agency

Read More

Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology

Read More

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

Read More

Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology

Read More

Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials

Read More

Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company

Read More

Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.

Read More